Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY.
Prime Medicine，Inc.（納斯達克：PRME）是一家生物技術公司，致力於提供新型的基因編輯療法，並推出更加具有差異化的一次性治癒性基因療法。今天，2024年5月13日，該公司宣佈，Prime Medicine的首席財務官Allan Reine醫生將於2024年5月20日星期一下午4:30 ET，在紐約納斯達克參加H.C. Wainwright第二屆BioConnect投資者會議上的爐邊聊天。
A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the presentation.
公司網站的“新聞與事件”中的“事件和演示文稿”將提供本次爐邊聊天的現場音頻網絡直播。www.primemedicine.com。演示文稿結束後，Prime Medicine網站將提供90天的網絡直播回放。
About Prime Medicine
關於Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing's versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine是一家領先的生物技術公司，致力於爲患者創造和提供下一代基因編輯療法。該公司正在使用其專有的Prime Editing平台發展一種差異化、一次性的治癒性基因療法。Prime Editing平台可在基因內僅進行正確編輯，同時最小化不必要的DNA修飾，使Prime編輯器在許多不同的組織、器官和細胞類型中修復幾乎所有類型的基因突變，並展現了其巨大的治療潛力。Prime Medicine目前正在推進各種治療項目組合：血液學和免疫學、肝臟、肺、眼科和神經肌肉。每個主要領域，Prime Medicine的初步重點是治療患者進行快速、直接的遺傳病治療，並針對目前無法使用其他基因編輯方法進行治療的高度不滿足需求的遺傳疾病。隨着時間的推移，Prime Medicine計劃最大程度發揮Prime Editing的廣泛和多樣化的治療潛力，擴展其初步管道以超出遺傳疾病，可能包括免疫性疾病、癌症、傳染病和有共同疾病的基因風險因素的靶向，這些疾病共影響數百萬人。欲知更多信息，請訪問
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular. Across each core area, Prime Medicine's initial focus is on genetic diseases with a fast, direct path to treating patients, and those with high unmet need not currently addressable using other gene editing approaches. Over time, the Company intends to maximize Prime Editing's broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
www.primemedicine.com現階段已將調查型治療計劃大力推進，並整合核心專業領域：血液學和免疫學、肝臟、肺、眼科以及神經肌肉。在每一個專業領域，Prime Medicine的初始焦點是針對直接向患者進行快速基因治療、目前無法使用其他基因編輯方法治療的遺傳性疾病。隨着時間的推移，公司打算最大限度地發揮Prime Editing平台廣泛而多樣化的治療潛力，超越特定的遺傳性疾病，向各種疾病擴展使用。 而這些疾病包括免疫性疾病、癌症、傳染病和有共同疾病的基因風險因素的靶向，共影響數百萬人。www.primemedicine.com.
2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
2024年Prime Medicine, Inc.。保留所有權利。PRIME MEDICINE、Prime Medicine標識和PASSIGE是Prime Medicine, Inc.的商標。此處提到的所有其他商標均爲其各自所有者的財產。
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
投資者聯繫方式
漢娜·德里西維茨
過於投資者關係公司
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
媒體聯繫人
丹·巴德威克，1AB
dan@1ABmedia.com
譯文內容由第三人軟體翻譯。